Navigating Early versus Late Toxicities with CAR T in Myeloma

Panelists discuss the correlation between early and late toxicities observed in clinical practice for patients receiving chimeric antigen receptor T-cell (CAR T) therapy in early relapsed/refractory multiple myeloma and their perceptions of the latest International Myeloma Working Group Consensus Guidelines on response assessment and management of CAR T–related adverse events.

EP: 1.A 60-Year-Old Man With Early Relapse Multiple Myeloma

EP: 2.Identification, Evaluation, and Management of High-Risk Disease in Early R/R MM

EP: 3.Overview of Referral of CAR T for Early R/R Multiple Myeloma

EP: 4.CARTITUDE-4: Latest Data of Cilta-Cel for Early R/R MM

Now Viewing

EP: 5.Navigating Early versus Late Toxicities with CAR T in Myeloma

Video content above is prompted by the following:

• For patients receiving chimeric antigen receptor T-cell (CAR T) in early relapsed/refractory multiple myeloma, how do toxicities (ie, early, late) correlate to those observed in practice?
• What are your perceptions of the latest International Myeloma Working Group Consensus Guidelines surrounding the response/management of CAR T, specifically adverse events?

Recent Videos